Mosby's 2014 Nursing Drug Reference (340 page)

BOOK: Mosby's 2014 Nursing Drug Reference
11.6Mb size Format: txt, pdf, ePub
QUEtiapine (Rx)

(kwe-tie′a-peen)

Seroquel, Seroquel XR

Func. class.:
Antipsychotic, atypical

Chem. class.:
Dibenzothiazepine

ACTION:

Functions as an antagonist at multiple neurotransmitter receptors in the brain, including 5HT
1A
, 5HT
2
, dopamine D
1
, D
2
, H
1
, and adrenergic α
1
, α
2
receptors

USES:

Bipolar disorder, bipolar I disorder, depression, mania, schizophrenia

Unlabeled uses:
Agitation, dementia, OCD, acute psychosis

CONTRAINDICATIONS:

Hypersensitivity, breastfeeding

Precautions:
Pregnancy (C), geriatric patients, hepatic/cardiac disease, breast cancer, long-term use, seizures, QT prolongation, brain tumor, hematologic disease, torsades de pointes, cataracts, dehydration, abrupt discontinuation

 

Black Box Warning:

Children, suicidal ideation, increased mortality in elderly patients with dementia-related psychosis

DOSAGE AND ROUTES
Calculator
Bipolar I disorder

• Adult:
PO
(monotherapy or adjunct to lithium, divalproex), not at increased risk for hypotension 50 mg bid on day 1, 100 mg on day 2 in 2 divided doses as tolerated to 400 mg/day on day 4, range 400-800 mg/day

• Geriatric, debilitated, or at risk for hypotension:
PO
25 mg bid, titrate upward slowly

• Child ≥10 yr/adolescents:
PO
25 mg bid day 1, 50 mg, bid day 2, 100 mg bid day 3, 150 mg bid day 4, 300 mg bid beginning day 5 dose adjusted

Schizophrenia

• Adult:
PO
(not at risk for hypotension) 25 mg bid, titrate upward; (XR) 300 mg/day in
PM
, range 400-800 mg/day

Depressive disorder (inadequate response to antidepressants alone)

• Adult:
PO EXT REL
50 mg/day in
PM
on days 1, 2; on day 3, give 150 mg in
PM

• Geriatric, debilitated or at risk for hypotension:
PO EXT REL
50 mg, may increase by 50 mg/day based on response

Available forms:
Tabs 25, 50, 100, 200, 300, 400 mg; ext rel tab 50, 150, 200, 300, 400 mg

Administer:

• 
Reduced dose to geriatric patients

• 
Anticholinergic agent on order from prescriber for EPS

• 
Avoid use of CNS depressants

• 
Immediate release:
without regard to meals

• 
Ext rel:
without food or with light meal ≤300 calories; swallow whole; do not split, crush, chew, can switch from immediate release to extended release by giving total daily dose q day

SIDE EFFECTS

CNS:
EPS, pseudoparkinsonism, akathisia, dystonia, tardive dyskinesia;
drowsiness
, insomnia, agitation, anxiety,
headache
,
seizures, neuroleptic malignant syndrome,
dizziness
, dystonia, restless legs

CV:
Orthostatic hypotension,
tachycardia, QT prolongation,
CV disease, Parkinson’s disease, cardiomyopathy, myocarditis

ENDO:
SIADH, hyperglycemia

GI:
Nausea, anorexia, constipation
, abdominal pain, dry mouth

HEMA:
Leukopenia, agranulocytosis

INTEG:
Rash

META:
Hyponatremia

MISC:
Asthenia, back pain, fever, ear pain

MS:
Rhabdomyolysis

RESP:
Rhinitis

SYST:
Stevens-Johnson syndrome, anaphylaxis

PHARMACOKINETICS

Extensively metabolized by liver, half-life ≥6 hr, peak 1½ hr, ext rel 6 hr, inhibits P450 CYP3A4 enzyme system, 83% protein binding, excretion: 73% urine, 20% feces

INTERACTIONS

 
Increase:
QT prolongation—class IA/III antidysrhythmics, some phenothiazines, β-agonists, local anesthetics, tricyclics, haloperidol, methadone, chloroquine, clarithromycin, droperidol, erythromycin, pentamidine

Increase:
CNS depression—alcohol, opioid analgesics, sedative/hypnotics, antihistamines

Increase:
hypotension—alcohol, antihypertensives

Increase:
QUEtiapine clearance, decrease QUEtiapine effect—phenytoin,
thioridazine, barbiturates, glucocorticoids, carBAMazepine, rifampin

Increase:
QUEtiapine action—fluconazole, itraconazole, ketoconazole (CYP3A4 inhibitors)

Increase:
effects of erythromycin

Decrease:
QUEtiapine clearance—cimetidine

Decrease:
effects of DOPamine agonists, levodopa, LORazepam

Drug/Lab Test

Increase:
cholesterol, triglycerides, LFTs, glucose

Decrease:
thyroid tests, WBC

NURSING CONSIDERATIONS
Assess:

 
CV status: QT prolongation, tachycardia, orthostatic B/P

 

Black Box Warning:

Mental status before initial administration, AIMS assessment; affect, orientation, LOC, reflexes, gait, coordination, sleep pattern disturbances; suicidal thoughts/behaviors (child/young adult); dementia (geriatric patients)

 
Suicide:
restrict amount of product given; usually suicidal thoughts/behaviors occur early during treatment and among children/adolescents/young adults

• 
Baseline blood glucose, LFTs, neurologic function, ophthalmologic exam, cholesterol profile, weight, monitor glucose often in diabetes mellitus

• 
B/P standing, lying; pulse, respirations; determine q4hr during initial treatment; establish baseline before starting treatment; report drops of 30 mm Hg; watch for ECG changes

• 
Dizziness, faintness, palpitations, tachycardia on rising

• 
EPS:
including akathisia (inability to sit still, no pattern to movements), tardive dyskinesia (bizarre movements of jaw, mouth, tongue, extremities), pseudoparkinsonism (rigidity, tremors, pill rolling, shuffling gait)

 
Neuroleptic malignant syndrome:
hyperthermia, increased CPK, altered mental status, muscle rigidity, seizures, tachycardia, diaphoresis, hypo/hypertension, fatigue; notify prescriber immediately if symptoms occur

• 
Constipation, urinary retention daily; if these occur, increase bulk, water in diet

Perform/provide:

• 
Supervised ambulation until patient stabilized on medication; do not involve patient in strenuous exercise program because fainting possible; patient should not stand still for long period of time

• 
Storage in tight, light-resistant container

Evaluate:

• 
Therapeutic response: decrease in emotional excitement, hallucinations, delusions, paranoia; reorganization of patterns of thought, speech

Teach patient/family:

• 
Not to become overheated

• 
Not to use if pregnancy is planned or suspected, not to breastfeed

• 
To rise slowly to prevent orthostatic hypotension

• 
To take medication only as prescribed, not to crush, chew ext rel product, not to use with alcohol, to take regular tabs without regard to food, ext rel without food

• 
That follow-up is necessary, including LFTs, blood glucose, neurologic, cholesterol profile, weight

• 
If drowsiness occurs, to avoid hazardous activities such as driving, not to stand quickly, may be worse during first few days of dose change

• 
To avoid use of OTC meds unless directed by prescriber

• 
To notify prescriber if pregnancy planned, suspected; not to breastfeed

• 
To notify prescriber immediately of fever, difficulty breathing, fatigue, sore throat, rash, bleeding

• 
Suicide:
thoughts/behaviors, primarily among children/adolescents/young adults

• 
To have eye exam before treatment and q6mo, cataracts may occur

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

Other books

The Good Father by Tara Taylor Quinn
Uncaged Love by JJ Knight
White Ute Dreaming by Scot Gardner
Deadly Fall by Susan Calder
Althea by Madeleine E. Robins
Deceptive Nights by Sylvia Hubbard
Home for the Holidays by Johanna Lindsey